The pharmaceutical portfolio for the treatment of CKD has considerably grown lately, as renin-angiotensin system inhibitors,9 sodium-glucose cotransporter-2 inhibitors,10 and (in diabetic patients) glucagon-like peptide-1 receptor agonists11 and mineralocorticoid receptor antagonists12 significantly halted the progression of CKD in prospective randomized trials. This evidence concerns the gene GLP1R and chronic kidney disease.